I thought too what little I've read their technology seems interesting and Genzyme backing certainly gives credability. But I would think they will have to do studies in each specific indication especially since their are different end-points. My understanding is they are initially targeting a subset of MD. I also think Genzyme is in no hurry to advance a competing therapy so I wouldn't expect too rapid of development in Pompe especially.
Market Data 
Markets 
AI
